Trial Profile
Sun Yat-sen University Cancer Center
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 15 Mar 2022 Results The cutoff date was November 03, 2020 published in the BMC Cancer
- 13 Jul 2020 Status changed from recruiting to completed.
- 31 May 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.